aTYR PHARMA (LIFE) saw its loss narrow to $12.57 million, or $0.53 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $16.49 million, or $0.70 a share.

The company has not recorded any revenues for the current as well as previous quarter.

Operating loss for the quarter was $12.53 million, compared with an operating loss of $16.48 million in the previous year period.

"During the past year, we made significant progress in our mission to develop and ultimately deliver innovative therapeutics, based on novel immunological pathways, to patients with severe and rare diseases. Last year, we announced data from four separate clinical trials for Resolaris for the treatment of patients in three rare myopathy indications where immune cells play a role," said John Mendlein, PhD, chief executive officer of aTyr Pharma. "In addition, we advanced our Stalaris program for rare lung diseases pre-clinically and plan to initiate clinical development in the second half of 2017. Finally, we created a third program based on our proprietary immunological pathways involving Physiocrine biology in a distinctly different therapeutic area, code named ‘Project ORCA’, and will announce more details later this year.”